These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 9057726)
1. How should we proceed with disease-modifying treatments for multiple sclerosis? Andersson PB; Waubant E; Goodkin DE Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726 [No Abstract] [Full Text] [Related]
2. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
3. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S; Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241 [No Abstract] [Full Text] [Related]
4. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
5. [Multiple sclerosis--recent advances in pathogenesis and treatment]. Itoyama Y; Fujihara K; Nakashima I; Misu T; Fujimori T; Sato S No To Shinkei; 2002 Jan; 54(1):5-21. PubMed ID: 11868352 [No Abstract] [Full Text] [Related]
6. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
7. Therapy of multiple sclerosis in children and adolescents. Tenembaum SN Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159 [TBL] [Abstract][Full Text] [Related]
8. Update on MS treatment. Ryan M J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740 [No Abstract] [Full Text] [Related]
9. [Recent progress in treatment for multiple sclerosis]. Kira J Rinsho Shinkeigaku; 2000 Dec; 40(12):1261-3. PubMed ID: 11464473 [TBL] [Abstract][Full Text] [Related]
16. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317 [No Abstract] [Full Text] [Related]